Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCPVax in Metastatic NSCLC
NCT02818426Phase 2Completed
- Sponsor
- CHU de Besançon
- Start
- Apr 2016
- Primary completion
- Aug 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of UCPVax in non-small cell lung cancer (NSCLC), sponsored by CHU de Besançon. Started Apr 2016; status: completed.
02
Drugs
UCPVax
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02818426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02818426.